Skip to content

April 29, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
M&A / Deals
Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact

M&A / Deals

Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact

Pharmaceutical Technology

Eli Lilly and Profluent will harness AI to discover and develop recombinases for precise, large-scale gene editing.

Read full story

pharminent April 29, 2026 (Last updated: April 29, 2026)

Pharmaceutical Technology

Eli Lilly and Profluent will harness AI to discover and develop recombinases for precise, large-scale gene editing.

Read full story

Post navigation

Previous: The strategic investments expanding CDMO capabilities for HPAPIs and ADCs

Next: Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’

Related Stories

M&A / Deals

Arcera and Fosun sign MoU for neuroscience innovation

pharminent April 29, 2026

M&A / Deals

Rocket to sell PRV for $180m to advance gene therapy pipeline

pharminent April 29, 2026

M&A / Deals

AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B

pharminent April 28, 2026

You May Have Missed

Commercial

Pfizer settles with generic drugmakers to protect blockbuster drug until 2031

pharminent April 29, 2026

Regulatory

AZ, Amgen will pilot FDA’s real-time clinical trial plan

pharminent April 29, 2026

Regulatory

AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions

pharminent April 29, 2026

Commercial

Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’

pharminent April 29, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.